SOURCE-LINKED STUDY SUMMARY
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
What was studied?
A randomized phase 2 trial studied cagrilintide for weight management in adults without diabetes who had obesity, or overweight with hypertension or abnormal lipids.
What changed?
Estimated weight loss assuming adherence was 6.0–10.8% with cagrilintide versus 3.0% with placebo; 4.5 mg achieved 10.8% versus 9.0% with liraglutide. Gastrointestinal events occurred in 41–63% versus 32% with placebo; injection-site reactions were also frequent.
Who was studied?
706 participants were randomized; the primary outcome was percentage weight change at week 26.
Studied exposure
Subcutaneous cagrilintide targeted 0.3, 0.6, 1.2, 2.4 or 4.5 mg weekly, versus liraglutide 3 mg daily or placebo for 26 weeks, including up to six weeks of escalation.
What remains uncertain?
Participants and investigators were not masked to differences between active treatments.
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1016/s0140-6736(21)01751-7